Amgen is among the seed investors for Stanford-licensed drug release technology developer Navan Technologies, which hopes its nanoinjection technique will enable more cell and gene therapies to be produced at scale.
Navan Technologies, a US-based drug release technology developer based on Stanford University research, closed a seed round of undisclosed size on Thursday led by Amgen Ventures, the corporate venturing division of pharmaceutical firm Amgen.
Amgen Ventures was joined in the round by public-private partnership High-Tech Gründerfonds (HTGF), Hemi Ventures and unnamed institutional and private investors.
Founded in 2016, Navan Technologies has designed a drug delivery technique branded NanoStraw that enables cell and gene-based medicines to reach their target…